N/A
N=10
Protection of Rectum From High Radiation Doses
Prostate Cancer
Bottom Line
View on ClinicalTrials.gov: NCT01601691 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Nov 2014
Primary outcome: Primary: Spacer Volume Half Life — 47 days
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- DuraSeal (Device)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- Male
- Sponsor
- University of Oulu
- Primary completion
- Jan 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Spacer Volume Half Life |
47 | — |
| SECONDARY Side Effects |
— | — |
| SECONDARY Rectum Radiation Dose |
— | — |
Summary
The purpose of this study is to evaluate the usefulness of diluted DuraSeal product as a spacer between prostate and rectum in prostate cancer low dose brachytherapy.
Eligibility Criteria
Inclusion Criteria
- prostate cancer patients with planned low dose brachytherapy for the treatment of prostate cancer
Exclusion Criteria
- not willing to participate this study
Data sourced from ClinicalTrials.gov (NCT01601691). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.